Zansit Tablet contains Sitagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Sitagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the levels of incretin hormones, thereby increasing insulin release from pancreatic beta cells and decreasing glucagon secretion from alpha cells in a glucose-dependent manner. This dual action helps improve glycemic control by reducing fasting and postprandial blood glucose levels. Zansit is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The recommended dose is typically 50 mg once daily, with dosage adjustments based on renal function. Zansit is generally well tolerated, with a low risk of hypoglycemia when used as monotherapy. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections. Caution is advised in patients with renal impairment, and regular monitoring of blood glucose and renal function is recommended during therapy. Zansit should be used under medical supervision as part of a comprehensive diabetes management plan.